Physician profile
Nagendra Myneni
NPI 1649238643
$66,397.42
in general payments reported to CMS, 2019-2025
36 companies · $15K in 2025
The $15K reported for 2025 was more than what 94% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $2,468 · 2021: $2,895 · 2022: $2,032 · 2023: $1,427 · 2024: $23K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Food and Beverage: $6,541 · Travel and Lodging: $423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,465.00 |
| Food and Beverage | $6,540.64 |
| Travel and Lodging | $423.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $34,781.68 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13,202.32 | 2019-2024 | Xifaxan, Trulance, Uceris |
| Allergan, INC. | $10,410.42 | 2019 | |
| Abbvie INC. | $1,839.95 | 2019-2025 | |
| Janssen Biotech, INC. | $1,313.13 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $907.72 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Regeneron Healthcare Solutions, INC. | $499.60 | 2022-2025 | Dupixent |
| Pfizer INC. | $350.06 | 2019-2025 | |
| Madrigal Pharmaceuticals | $324.39 | 2025 | Rezdiffra |
| Lilly USA, LLC | $292.76 | 2024-2025 | Omvoh |
| Gilead Sciences, INC. | $256.67 | 2019-2025 | Epclusa |
| Janssen Scientific Affairs, LLC | $247.81 | 2019-2022 | |
| Celgene Corporation | $212.06 | 2022-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $160.04 | 2022-2023 | Rebyota |
| Merit Medical Systems INC | $135.00 | 2025 | Esophyx |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $130.95 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2021 | |
| Amgen INC. | $121.14 | 2021-2023 | Amjevita, Avsola |
| Merck Sharp & Dohme LLC | $117.63 | 2020-2024 | Dificid, Zinplava |
| E.R. Squibb & Sons, L.L.C. | $115.24 | 2024 | Zeposia |
| Medtronic, INC. | $112.45 | 2021-2022 | |
| Ucb, INC. | $103.26 | 2019-2024 | Cimzia |
| Novo Nordisk INC | $100.03 | 2025 | Wegovy |
| Ironwood Pharmaceuticals, INC | $84.76 | 2019-2025 | Linzess |
| Apollo Endosurgery US INC | $83.25 | 2022 | |
| Nestle Healthcare Nutrition INC. | $52.51 | 2021 | |
| Celltrion USA INC. | $51.31 | 2024-2025 | Vegzelma |
| Braintree Laboratories, INC. | $50.31 | 2020-2022 | |
| Ipsen Biopharmaceuticals, INC | $44.83 | 2025 | Iqirvo |
| Genzyme Corporation | $37.17 | 2025 | |
| Boston Scientific Corporation | $29.98 | 2023 | |
| Organon LLC | $24.10 | 2023-2024 | |
| Qol Medical, LLC | $23.76 | 2023 | Sucraid |
| Aimmune Therapeutics, INC. | $22.39 | 2025 | Zenpep |
| Covidien LP | $21.97 | 2019 | |
| Intercept Pharmaceuticals, INC. | $11.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nagendra Myneni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.